Kornimate/medical-research-clean huggingface dataset:
predictors of the quality of surgical reduction and long-term outcome

Conditions: Transverse Fracture of Acetabulum

Summary: acetabulum fractures are complex, relatively rare lesions linked to a more or less good functional prognosis and therefore represent a real surgical challenge. in the literature, it is accepted that surgical delay, among other things, negatively impacts the quality of surgical reduction. however, this reduction must be a major priority since it is one of the factors conditioning the functional result. in our study, we wish to analyze a particular type of fracture, less studied, or with small series, that are the transverse fractures (+/- posterior wall), known for their difficulty of reduction. the reduction is even greater as the fracture line often passes through the acetabular bearing zone, compromising the functional prognosis. the choice of surgical approach for this type of fracture is controversial. more and more, a single approach, usually posterior, without compulsory fixation of the anterior component of the transverse fracture is preferred over the traditional double approach anterior and posterior, and this in particular to reduce the morbidity of this surgery. but this one-size-fits-all approach does not always achieve a good reduction and it is believed that the time to surgery may play a role. if it is accepted that the surgical delay before reduction in osteosynthesis of an acetabular fracture is involved in the quality of the reduction and therefore the functional result in these patients, the question asked is whether this delay should condition the choice of a double approach, anterior and posterior, for this type of fracture (transverse +/- posterior wall). indeed, with increasing surgical time, the risk of scar tissue formation and early callus increases, making bone fragments less mobile, reduction more difficult and indirect reduction techniques (which are used when single approach is chosen) less efficient. in addition, most of the studies evaluating the quality of reduction of acetabular fractures use a radiographic score, that of matta. however, it has been shown that the ct scan was more efficient than the x-rays in detecting a residual displacement of the fracture. also, in this study, we want to analyze the quality of reduction thanks to the scanner, which is rarely done in the literature. this work aims to determine the predictive factors of the quality of reduction of transverse fractures +/- posterior wall of the acetabulum, evaluated on the postoperative ct scan.


Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * patient with transverse fractures +/- posterior wall of the acetabulum * patient cared for at paris saint-joseph hospital, between 2006 and 2020 * french-speaking patient exclusion criteria: * patient under guardianship or curatorship * patient under legal protection * patient deprived of liberty * patient not operated * patient with an undisplaced fracture * patient who did not have a post-operative control scan * patient objecting to the use of their data for this research
biomarkers in dyspnea

Conditions: Healthy Volunteers

Summary: to explore biological mechanisms in human model of induced dyspnea, in order to remove the source of dyspnoea, to modify cerebral impact and to allow the development of targeted therapies.

the aim of the study will be to identify a specific biology and immunology associated with dyspnoea. it will open therapeutic possibilities through a better understanding of the mechanisms of dyspnea. healthy volunteers will underwent two types of dyspnea. the subjects will be first familiar with both types of dyspnea and dyspnea measurement scales. different components of dyspnea will be measured. blood tests will be performed at different times (before dyspnea, during dyspnea, 60 and 90 min after dyspnea)

Eligibility criteria:
inclusion criteria: * healthy volunteers exclusion criteria: * pregnancy * ongoing pain * respiratory disease * high levels of depression, panic disorder, or other significant mental health problems * not fluent in french
delirium assessment in the pediatric intensive care unit

Conditions: Delirium

Summary: the aim of this study was to show the efficacy of non-pharmacological interventions on preventing pediatric delirium in pediatric intensive care unit

the aim of this study was to show the efficacy of non-pharmacological interventions on preventing pediatric delirium in pediatric intensive care unit. patients who is followed up for at least 48 hours in pediatric intensive care unit will be included in the study. parents of patients will be allowed to stay with the patient as long as the conditions of service is appropriate. parents will provide oral treatments to the patients. patients will be allowed to spend time with their phone, tablet or toy in accordance with their age. fellow resident will screen for pediatric delirium each child using the cornell assessment of pediatric delirium twice a day.

Eligibility criteria:
inclusion criteria: * pediatric cerebral performance category \< 5 points * patients who stay in picu \>48 hours exclusion criteria: * pediatric cerebral performance category \> 4 points * patients who stay in picu \<48 hours

Keywords: delirium pediatric intensive care
hemodynamic effect of prone position in non-intubated patient with covid 19

Conditions: Covid19; Pneumonia, Viral

Summary: prone position in non-intubated patient has shown some respiratory physiological benefits. prone positioning in patient intubated with ards has shown hemodynamic benefits. we aim to compare hemodynamic assessment before and after prone positioning in non-intubated patient with covid 19 pneumonia. the study hypothesis is that prone positioning in non-intubated patient improve right ventricular preload, reduce afterload and increase cardiac index compared to supine position.


Eligibility criteria:
inclusion criteria: * adult patient * covid 19 pneumonias with hypoxemia * for whom prone positioning has been decided by the attending physician. exclusion criteria: * mechanical ventilation * ecls

Keywords: covid 19 prone position hemodynamic effect spontaneous ventilation
clinical study of utidelone injection in patients with advanced non-small cell lung cancer（nsclc）

Conditions: Advanced Non-small Cell Lung Cancer

Summary: to assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic nsclc as a phase ii trial


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed non-small cell lung cancer 2. nsclc patients who are not suitable for surgery or radical radiotherapy or chemotherapy, or who have failed to or are intolerable for standard treatment in local advanced or metastatic nsclc; 3. nsclc patients failed or intolerable to previous standard second-line treatment (including platinum chemotherapy or targeted therapy); 4. patients who did not receive chemotherapy, radiotherapy, surgical therapy, molecularly targeted drug therapy, or immunotherapy 4 weeks prior to enrollment; 5. age 18 -70 years old, ecog performance status of 0-1; life expectancy of 3 months or more; 6. patients must have measurable disease, defined as at least one target lesion that can be accurately measured by imaging techniques in at least one dimension as ≥20 mm with conventional computed tomography (ct), ≥10 mm with spiral ct scan (≥15mm for lymph node) within 3 weeks before enrolment; 7. patients with no brain metastases or with brain metastases but are stable for more than 4 weeks after treatment; 8. peripheral neuropathy (pn) \<grade 2 on the common terminology criteria for adverse events (ctcae) version 4.03 within 4 weeks before enrolment; 9. patients must have normal haematology as defined below: hgb ≥9 g/l, absolute neutrophil count ≥1.5×109/l, platelets ≥80×109/l, bilirubin ≤1.5× the upper limit of normal (uln) (patients with liver metastasis ≤3xuln), aspartate transaminase (ast)/ alanine transaminase (alt) ≤2.5 ×uln (patients with liver metastasis ≤5xuln), and creatinine clearance ≥45 ml/min; 10. patients with no major organ dysfunctions and heart disease; 11. patients who give written informed consent with good compliance. exclusion criteria: 1. patients who are pregnant or breast feeding; 2. patients with active tuberculosis 3. patients with high possibility of interstitial lung disease ; 4. patients with comorbidities, such as carcinomatous meningitis, central nervous system (cns) metastasis, other active malignancies requiring simultaneous treatment, but not including cervical cancer in situ or basal cell carcinoma of the skin, severe disorders of the heart, lung, liver, or kidneys, severe hypertension, uncontrolled diabetes, severe gastrointestinal ulceration, active infections in need of antibiotics, or with incontrollable psychiatric history; 5. patients with hiv, untreated active hepatitis； 6. patients with poor compliance; 7. patients not fitted for this study determined by the investigators.
intravascular access in suspected/confirmed covid-19 patient

Conditions: Emergency Medicine; Cardiopulmonary Arrest; Shock

Summary: the current covid-19 pandemic, this is especially since the transmission of sars-cov-2 is thought to occur mainly through respiratory droplets generated by coughing and sneezing, by direct contact with contaminated surfaces and because in a large number of patients covid-19 disease may be asymptomatic. as recommended by the cdc medical personnel should be equipped with full personal protective equipment (ppe) for agp in contact with suspected/confirmed covid-19 patient. therefore, it is reasonable to search for the most effective methods of intravascular access in those conditions.


Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest (ohca) * adult ≥ 18 years old * non-traumatic cause of cardiac arrest exclusion criteria: * existing do-not-attempt-resuscitation order * ohca patients with contraindications to io access or iv access * patients with signs of obvious death, e.g. rigor mortis

Keywords: intravascular access intraosseous access personal protective equipment cardiopulmonary resuscitation shock
the turkish version of the inflammatory arthritis facilitators and barriers to physical activity

Conditions: Axial Spondyloarthritis

Summary: our aim in this study is to translate the inflammatory arthritis facilitators and barriers to physical activity (ifab) questionnaire which was developed to determine the factors that facilitate and prevent individuals for physical activity for patients with inflammatory arthritis into turkish language. also, our aim is to evaluate the validity and reliability of the ifab questionnaire in the turkish population, and to perform a cultural adaptation if necessary at the same time. determining the factors that facilitate and prevent individuals for physical activity interventions with rheumatic diseases and then designing physical activity programs considering these factors may play an important role in reducing the symptoms caused by the disease and increasing their quality of life.


Eligibility criteria:
inclusion criteria: * being 18 years or older, * diagnosed with axial spondyloarthritis by an experienced rheumatologist * to have the neurological competence and cognitive level to answer the scale questions. exclusion criteria: * having a rheumatological disease other than axial spondyloarthritis , * using an assistive device for walking. * any verbal or written communication problems in turkish,
open-label extension study to evaluate the safety and tolerability of wve-120101 in patients with huntington's disease

Conditions: Huntington Disease

Summary: wve-hdsnp1-002 is an open-label extension (ole) study to evaluate the safety, tolerability, pk, pd, and clinical effects of wve-120101 in adult patients with early manifest hd who carry a targeted single nucleotide polymorphism, rs362307 (snp1). to participate in the study, patients must have completed the phase 1b/2a clinical study wve-hdsnp1-001.


Eligibility criteria:
key inclusion criteria: * 1. patient successfully completed the phase 1b/2a study with wve-120101, wve-hdsnp1-001. key exclusion criteria: * 1. received an investigational drug other than wve-120101, including an investigational oligonucleotide, within the past 1 year or 5 half-lives of the drug, whichever is longer. * 2. inability to undergo brain mri (with or without sedation). * 3. clinically significant medical finding on the physical examination other than hd that, in the judgment of the investigator, will make the patient unsuitable for participation in and/or completion of the study procedures.
overcoming obstacles to clinical trials enrollment through a navigator program

Conditions: Genital Neoplasms, Female; Gynecologic Cancers; Breast Cancer

Summary: pilot study for assessing the effectiveness of a navigator program to aid in clinical trial participation amongst the chinese demographic


Eligibility criteria:
inclusion criteria: cancer patients for focus group must meet the following criterion: * diagnosis of any gynecologic or breast cancer and be pursuing treatment here at stanford within the last 2 years * must read and speak chinese * willing and able to participant in group discussions cancer patients to receive navigator support must meet the following criterion: * newly diagnosed with gynecologic or breast cancer -pursuing treatment at stanford cancer center * must read and speak chinese * willing and able to have an individual relationship with a navigator health professional must meet the following criterion: -must currently work in the stanford gynecologic oncology clinic navigators must meet the following criterion: * chinese and english speaking * willing and able to participate in training and to serve as a navigator * preferably a cancer survivor exclusion criteria: cancer patients must have a gog performance status of 0-2 (see attached document for further details). focus group participate may be able to be participating in another study but patients who are already participating in a clinical trial will not be assigned a navigator. no exclusionary criterion for health professionals or navigators.
treatment of covid-19 associated pneumonia with allogenic pooled olfactory mucosa-derived mesenchymal stem cells

Conditions: COVID; Covid-19; Coronavirus; Pneumonia; Pneumonia, Viral; Pneumonia, Interstitial; Sars-CoV2

Summary: treatment of patients with covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells

during the implementation of the project, it is planned to develop a method for the treatment of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells. the positive outlook for the effectiveness of mscs is due to the following: * knowledge of the leading role of immunopathogenetic mechanisms in the development of acute interstitial lung diseases and the pronounced immunomodulating properties of mscs; * high tropism of mscs to lung tissue when administered intravenously; * the ability of mscs to stimulate tissue regeneration and the effective use of mscs in the treatment of acute damage to the myocardium and kidneys, which will contribute to the treatment of multiple organ failure; * positive results of preclinical studies of the method of treatment of viral pneumonia in animals, and the first clinical studies in patients.

Eligibility criteria:
inclusion criteria: * pcr-confirmed covid-19 pneumonia * respiratory failure exclusion criteria: * diagnosed cancer

Keywords: pneumonia sars-cov2 covid-19
effects of horse riding simulator with or without visual feedback on balance and postural control

Conditions: Cerebral Palsy

Summary: spastic cerebral palsy is a neurological condition that causes muscle spasticity and motor impairments, greatly impacting a child's ability to maintain balance and control their posture. the horse riding simulator (hrs), inspired by hippo therapy, has emerged as a potential therapeutic intervention for enhancing motor function in individuals with cerebral palsy. this study explored the additional effects of mirror visual feedback when used in conjunction with the hrs. strategically placed mirrors allow participants to observe their own body movements and positions in real-time. the simulator's rhythmic, multidimensional movements deliver sensory input and challenge the motor system, promoting postural adjustments and improved balance. furthermore, the integration of mirror visual feedback appears to enhance the therapeutic benefits. real-time visual information enables children to actively observe and correct their body positioning, leading to improved body awareness and more efficient motor responses.

cerebral palsy (cp), one of the most common physical disabilities in childhood, is a disorder of movement and posture caused by non-progressive lesions in the developing brain. children with cp, to varying degrees, have muscle weakness, tone abnormality, and motor-control impairment, causing abnormal posture and poor balance control.in high-income countries, the current birth prevalence of cerebral palsy has decreased to 1.6 per 1000 live births. however, in low- and middle-income countries, the birth prevalence is significantly higher. children diagnosed with cp exhibit a range of muscle weakness, tone abnormalities, and impaired motor control. these factors contribute to abnormal posture and compromised control over balance

Eligibility criteria:
inclusion criteria: * spastic cerebral palsy with level i and ii according to gross motor function classification system (gmfcs) * age between 8 and 12 years * ability to sit and stand independently * both genders are included (female and male) exclusion criteria: * having received an injection of botulinum toxin within 3 months * having undergone orthopedic surgery or selective dorsal rhizotomy in the previous 1 year * having undergone hrs training within 6 months; * having severe pain, joint dislocation, contracture, or spinal deformity * having experienced uncontrolled epileptic seizure * having poor visual or hearing acuity.

Keywords: balance cerebral palsy horse riding simulator (hrs) posture control
neutrophil extracellular traps as a biomarker to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma

Conditions: Neutrophil Extracellular Trap Formation; Portal Vein Tumor Thrombosis

Summary: the aim of this study was to investigate whether nets markers can enhance predict portal vein tumor thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.

eighty-six patients with patients treated at the affiliated hospital of qingdao university (china) from september 2020 to january 2021 were recruited for this study, including 14 patients with portal vein tumor thrombosis, 28 patients without portal vein tumor thrombosis and 44 patients without hepatocellular carcinoma. nets markers (myeloperoxidase, neutrophil elastase, citrate histone h3), and anti-β2 glycoprotein i were detected in plasma using capture elisa and specific elisa kits. t-test was performed to analyze whether there was a statistical difference between the two groups, and regression analysis was performed between nets markers and tissue factor and anti-β2 glycoprotein i to investigate whether there was a correlation. this study without any intervention measures, will not cause harm.

Eligibility criteria:
inclusion criteria: （1) clinical diagnosis of hcc with liver cirhosis (2) clinical diagnosis of portal vein tumor thrombosis exclusion criteria: (1) secondary liver malignancy (2)hematologic diseases (3) bud-chiah syndrome (4) incomplete data

Keywords: neutrophil extracellular trap portal vein tumor thrombosis
a study of pimavanserin for the treatment of agitation and aggression in subjects with alzheimer's disease

Conditions: Agitation and Aggression in Alzheimer's Disease

Summary: to evaluate the safety and tolerability of pimavanserin over 52 weeks of treatment in subjects with probable ad who have symptoms of agitation and aggression


Eligibility criteria:
inclusion criteria: 1. must complete the week 12 visit in study acp-103-032 while continuing to take his/her assigned dose of blinded study drug 2. can understand the nature of the trial and protocol requirements and provide signed informed consent * from patient, if deemed competent to provide consent * from an appropriate person (e.g. patient's legally authorized representative (lar) with the patient's assent) if patient is deemed not competent to provide informed consent. 3. lives at home or in an assisted living or care facility (but has the capacity to visit the clinic as an outpatient) 4. has a designated study partner/caregiver who is in contact with the patient at least 3 times a week on 3 separate days 5. female patients must be of non-childbearing potential or must agree to use an acceptable method of contraception or abstinence, during the study, and 1 month following completion of the study 6. the patient and caregiver are willing and able to participate in all schedule evaluations and complete all required tests exclusion criteria: 1. patient was significantly non-compliant in study acp-103-032 2. the investigator becomes aware of an impending and unexpected change in the patient's living situation (e.g., change in caregiver, change in facility, moving from home to facility, moving from one family member or caregiver's home to another) that may cause a major disruption in the patient's behavior 3. patient or study partner/caregiver has a medical condition (e.g., hearing, vision impairments) that would impair the ability to perform the study assessments. 4. patient is bedridden or has any significant medical condition that is unstable and would place the patient at undue risk from study drug or study procedures 5. has clinically significant laboratory abnormalities that would jeopardize the safe participation of the patient in the study 6. has a global clinician assessment of suicidality (gcas) score of 3 or 4 based on investigator's assessment of behavior since the last assessment